Q5107 HCPCS code: Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
Q5107 is the HCPCS Level II code for injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg. In 2024 Medicare paid an average of $20.13 per service for Q5107 across 1,123,996 services. Its Medicare coverage code is D (Special coverage instructions apply): Medicare covers it when its national or local coverage criteria are met. The NCCI unit limit is 230 per day on outpatient hospital claims. Medicare volume fell 53% from 2022 to 2024 (2,387,328 to 1,123,996 services). In 2024, about 2,181 clinicians billed Medicare for Q5107 for 3,074 beneficiaries; Texas, California, Tennessee accounted for 42% of services.
Code details
| Field | Value |
|---|---|
| Section | Q codes — Temporary codes |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2019-01-01 |
| Last action effective | 2019-01-01 |
Who bills Q5107 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 2,181 |
| Medicare beneficiaries | 3,074 |
| States with claims | 33 |
| Share of services in top 3 states (Texas, California, Tennessee) | 42% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for Q5107, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 2,387,328 | 5,520 | $34.38 | $27.45 |
| 2023 | 1,554,957 | 3,626 | $28.33 | $22.55 |
| 2024 | 1,123,996 | 3,074 | $25.30 | $20.13 |
States with the most Q5107 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Texas | 174,750 | $20.25 |
| California | 167,157 | $20.41 |
| Tennessee | 117,694 | $20.40 |
| Illinois | 64,722 | $20.23 |
| Maryland | 62,080 | $20.42 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 230 | CMS Policy |
| practitioner claims | 230 | CMS Policy |
Medicare policy articles for this code
- A52370: Billing and Coding: Bevacizumab and biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B))
Covered diagnoses (458 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| C17.0 | Malignant neoplasm of duodenum | 1 |
| C17.1 | Malignant neoplasm of jejunum | 1 |
| C17.2 | Malignant neoplasm of ileum | 1 |
| C17.3 | Meckel's diverticulum, malignant | 1 |
| C17.8 | Malignant neoplasm of overlapping sites of small intestine | 1 |
| C17.9 | Malignant neoplasm of small intestine, unspecified | 1 |
| C18.0 | Malignant neoplasm of cecum | 1 |
| C18.1 | Malignant neoplasm of appendix | 1 |
| C18.2 | Malignant neoplasm of ascending colon | 1 |
| C18.3 | Malignant neoplasm of hepatic flexure | 1 |
Showing 10 of 458. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for Q5107
- 2019-01-01: Q5107 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code Q5107?
Q5107 is the HCPCS Level II code for injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg. Short descriptor: "Inj mvasi 10 mg".
How much does Medicare pay for Q5107?
In 2024, the average Medicare payment was $20.13 per service (average allowed $25.30).
Does Medicare cover Q5107?
Coverage code D — Special coverage instructions apply. Medicare covers it when its national or local coverage criteria are met.
Which diagnoses support coverage for Q5107?
Medicare policy articles that cite Q5107 list 458 covered ICD-10-CM diagnosis codes across 1 article. The most cited include C17.0 (Malignant neoplasm of duodenum), C17.1 (Malignant neoplasm of jejunum), C17.2 (Malignant neoplasm of ileum). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of Q5107 can be billed per day?
230 on outpatient hospital claims; 230 on practitioner claims (NCCI medically unlikely edits).
Related Q51 codes
- Q5100 — Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg
- Q5101 — Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
- Q5102 — Injection, infliximab, biosimilar, 10 mg
- Q5103 — Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
- Q5104 — Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
- Q5105 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units
- Q5106 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
- Q5108 — Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
- Q5109 — Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg
- Q5110 — Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
- Q5111 — Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
- Q5112 — Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under Q5107
- Watch Q5107 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q5107
Sources: CMS HCPCS Level II release October 2025; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.